Literature DB >> 18785768

Snake venomics of the Lesser Antillean pit vipers Bothrops caribbaeus and Bothrops lanceolatus: correlation with toxicological activities and immunoreactivity of a heterologous antivenom.

José María Gutiérrez1, Libia Sanz, José Escolano, Julián Fernández, Bruno Lomonte, Yamileth Angulo, Alexandra Rucavado, David A Warrell, Juan J Calvete.   

Abstract

The venom proteomes of the snakes Bothrops caribbaeus and Bothrops lanceolatus, endemic to the Lesser Antillean islands of Saint Lucia and Martinique, respectively, were characterized by reverse-phase HPLC fractionation, followed by analysis of each chromatographic fraction by SDS-PAGE, N-terminal sequencing, MALDI-TOF mass fingerprinting, and collision-induced dissociation tandem mass spectrometry of tryptic peptides. The venoms contain proteins belonging to seven ( B. caribbaeus) and five ( B. lanceolatus) types of toxins. B. caribbaeus and B. lanceolatus venoms contain phospholipases A 2, serine proteinases, l-amino acid oxidases and zinc-dependent metalloproteinases, whereas a long disintegrin, DC-fragments and a CRISP molecule were present only in the venom of B. caribbaeus, and a C-type lectin-like molecule was characterized in the venom of B. lanceolatus. Compositional differences between venoms among closely related species from different geographic regions may be due to evolutionary environmental pressure acting on isolated populations. The venoms of these two species differed in the composition and the relative abundance of their component toxins, but they exhibited similar toxicological and enzymatic profiles in mice, characterized by lethal, hemorrhagic, edema-forming, phospholipase A 2 and proteolytic activities. The venoms of B. caribbaeus and B. lanceolatus are devoid of coagulant and defibrinogenating effects and induce only mild local myotoxicity in mice. The characteristic thrombotic effect described in human envenomings by these species was not reproduced in the mouse model. The toxicological profile observed is consistent with the abundance of metalloproteinases, PLA 2s and serine proteinases in the venoms. A polyvalent (Crotalinae) antivenom produced in Costa Rica was able to immunodeplete approximately 80% of the proteins from both B. caribbaeus and B. lanceolatus venoms, and was effective in neutralizing the lethal, hemorrhagic, phospholipase A 2 and proteolytic activities of these venoms.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18785768     DOI: 10.1021/pr8003826

Source DB:  PubMed          Journal:  J Proteome Res        ISSN: 1535-3893            Impact factor:   4.466


  30 in total

1.  Antivenomic assessment of the immunological reactivity of EchiTAb-Plus-ICP, an antivenom for the treatment of snakebite envenoming in sub-Saharan Africa.

Authors:  Juan J Calvete; Pedro Cid; Libia Sanz; Alvaro Segura; Mauren Villalta; María Herrera; Guillermo León; Robert Harrison; Nandul Durfa; Abdusalami Nasidi; R David G Theakston; David A Warrell; José María Gutiérrez
Journal:  Am J Trop Med Hyg       Date:  2010-06       Impact factor: 2.345

2.  Clinical and Evolutionary Implications of Dynamic Coagulotoxicity Divergences in Bothrops (Lancehead Pit Viper) Venoms.

Authors:  Lachlan Allan Bourke; Christina N Zdenek; Anita Mitico Tanaka-Azevedo; Giovanni Perez Machado Silveira; Sávio Stefanini Sant'Anna; Kathleen Fernandes Grego; Caroline Fabri Bittencourt Rodrigues; Bryan Grieg Fry
Journal:  Toxins (Basel)       Date:  2022-04-22       Impact factor: 5.075

3.  Differential evolution and neofunctionalization of snake venom metalloprotease domains.

Authors:  Andreas Brust; Kartik Sunagar; Eivind A B Undheim; Irina Vetter; Daryl C Yang; Dary C Yang; Nicholas R Casewell; Timothy N W Jackson; Ivan Koludarov; Paul F Alewood; Wayne C Hodgson; Richard J Lewis; Glenn F King; Agostinho Antunes; Iwan Hendrikx; Bryan G Fry
Journal:  Mol Cell Proteomics       Date:  2012-12-12       Impact factor: 5.911

4.  Case Report: Bothrops lanceolatus Snakebite Surgical Management-Relevance of Fasciotomy.

Authors:  M Severyns; R Nevière; D Resiere; T Andriamananaivo; L Decaestecker; H Mehdaoui; G A Odri; J L Rouvillain
Journal:  Am J Trop Med Hyg       Date:  2018-11       Impact factor: 2.345

Review 5.  New approaches & technologies of venomics to meet the challenge of human envenoming by snakebites in India.

Authors:  David A Warrell; José Maria Gutiérrez; Juan J Calvete; David Williams
Journal:  Indian J Med Res       Date:  2013       Impact factor: 2.375

6.  A transcriptomic analysis of gene expression in the venom gland of the snake Bothrops alternatus (urutu).

Authors:  Kiara C Cardoso; Márcio J Da Silva; Gustavo G L Costa; Tatiana T Torres; Luiz Eduardo V Del Bem; Ramon O Vidal; Marcelo Menossi; Stephen Hyslop
Journal:  BMC Genomics       Date:  2010-10-26       Impact factor: 3.969

7.  Antivenomics of Atropoides mexicanus and Atropoides picadoi snake venoms: Relationship to the neutralization of toxic and enzymatic activities.

Authors:  José Antúnez; Julián Fernández; Bruno Lomonte; Yamileth Angulo; Libia Sanz; Alicia Pérez; Juan José Calvete; José María Gutiérrez
Journal:  J Venom Res       Date:  2010-09-30

8.  Bothrops lanceolatus bites: guidelines for severity assessment and emergent management.

Authors:  Dabor Resiere; Bruno Mégarbane; Ruddy Valentino; Hossein Mehdaoui; Laurent Thomas
Journal:  Toxins (Basel)       Date:  2010-01-22       Impact factor: 4.546

Review 9.  Omics meets biology: application to the design and preclinical assessment of antivenoms.

Authors:  Juan J Calvete; Libia Sanz; Davinia Pla; Bruno Lomonte; José María Gutiérrez
Journal:  Toxins (Basel)       Date:  2014-12-15       Impact factor: 4.546

10.  Comparison of phylogeny, venom composition and neutralization by antivenom in diverse species of bothrops complex.

Authors:  Leijiane F Sousa; Carolina A Nicolau; Pedro S Peixoto; Juliana L Bernardoni; Sâmella S Oliveira; José Antonio Portes-Junior; Rosa Helena V Mourão; Isa Lima-dos-Santos; Ida S Sano-Martins; Hipócrates M Chalkidis; Richard H Valente; Ana M Moura-da-Silva
Journal:  PLoS Negl Trop Dis       Date:  2013-09-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.